| Primary |
| Product Used For Unknown Indication |
15.8% |
| Infection |
13.3% |
| Pseudomonas Infection |
9.2% |
| Sepsis |
6.7% |
| Pyrexia |
5.8% |
| Device Related Infection |
5.0% |
| Febrile Neutropenia |
5.0% |
| Abdominal Sepsis |
4.2% |
| Bronchiectasis |
4.2% |
| Acute Myeloid Leukaemia |
3.3% |
| Infectious Peritonitis |
3.3% |
| Prophylactic Chemotherapy |
3.3% |
| Urinary Tract Infection |
3.3% |
| Bacterial Pyelonephritis |
2.5% |
| Bronchitis |
2.5% |
| Cystic Fibrosis |
2.5% |
| Infection Prophylaxis |
2.5% |
| Pneumonia |
2.5% |
| Prophylaxis |
2.5% |
| Pulmonary Tuberculosis |
2.5% |
|
| Pyrexia |
10.5% |
| Anaphylactic Shock |
7.9% |
| Hypersensitivity |
7.9% |
| Status Epilepticus |
7.9% |
| Swollen Tongue |
7.9% |
| Abortion Induced |
5.3% |
| Diarrhoea |
5.3% |
| Drug Interaction |
5.3% |
| Liver Disorder |
5.3% |
| Overdose |
5.3% |
| Pseudomembranous Colitis |
5.3% |
| Toxic Epidermal Necrolysis |
5.3% |
| Agranulocytosis |
2.6% |
| Anaphylactic Reaction |
2.6% |
| Antibiotic Level Above Therapeutic |
2.6% |
| Clostridium Difficile Colitis |
2.6% |
| Culture Positive |
2.6% |
| Death |
2.6% |
| Dermatitis Bullous |
2.6% |
| Dermatitis Exfoliative |
2.6% |
|
| Secondary |
| Product Used For Unknown Indication |
21.5% |
| Drug Use For Unknown Indication |
12.9% |
| Pseudomonas Infection |
11.7% |
| Device Related Infection |
7.4% |
| Infection Prophylaxis |
5.5% |
| Sepsis |
5.5% |
| Stem Cell Transplant |
3.7% |
| Abdominal Sepsis |
3.1% |
| Hypertension |
3.1% |
| Lymphocytic Leukaemia |
3.1% |
| Unevaluable Event |
3.1% |
| Acinetobacter Infection |
2.5% |
| Cystic Fibrosis |
2.5% |
| Enterobacter Infection |
2.5% |
| Pneumonia |
2.5% |
| Staphylococcal Infection |
2.5% |
| Anticoagulant Therapy |
1.8% |
| Bone Marrow Transplant |
1.8% |
| Osteomyelitis |
1.8% |
| Prophylaxis |
1.8% |
|
| Eosinophilia |
10.7% |
| Interstitial Lung Disease |
10.7% |
| Abortion Induced |
7.1% |
| Acute Respiratory Distress Syndrome |
7.1% |
| Neutropenia |
7.1% |
| Renal Tubular Necrosis |
7.1% |
| Anaemia |
3.6% |
| Ascites |
3.6% |
| Bradycardia |
3.6% |
| Clostridium Colitis |
3.6% |
| Drug Interaction |
3.6% |
| Dyspnoea |
3.6% |
| Eosinophilic Pneumonia |
3.6% |
| Headache |
3.6% |
| Hepatotoxicity |
3.6% |
| Hypotonia |
3.6% |
| Infection |
3.6% |
| International Normalised Ratio Increased |
3.6% |
| Obstructive Airways Disorder |
3.6% |
| Oculomucocutaneous Syndrome |
3.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
31.5% |
| Prophylaxis |
7.8% |
| Sepsis |
6.5% |
| Pneumonia |
6.3% |
| Acute Lymphocytic Leukaemia |
5.3% |
| Pyrexia |
4.8% |
| Acute Myeloid Leukaemia |
4.4% |
| Cancer Pain |
3.8% |
| Constipation |
3.8% |
| Rheumatoid Arthritis |
3.6% |
| Drug Use For Unknown Indication |
3.4% |
| Breast Cancer |
2.9% |
| Infection |
2.9% |
| Pharyngitis |
2.5% |
| Insomnia |
2.1% |
| Hypertension |
1.9% |
| Antifungal Prophylaxis |
1.7% |
| Upper Respiratory Tract Inflammation |
1.7% |
| Urinary Tract Infection |
1.7% |
| Aspergillosis |
1.5% |
|
| Death |
13.5% |
| Thrombocytopenia |
11.5% |
| Pyrexia |
7.7% |
| Sepsis |
5.8% |
| Cardiac Failure |
3.8% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.8% |
| Epilepsy |
3.8% |
| Infection |
3.8% |
| Kidney Transplant Rejection |
3.8% |
| Leukopenia |
3.8% |
| Lung Neoplasm Malignant |
3.8% |
| Pancytopenia |
3.8% |
| Peritonitis |
3.8% |
| Platelet Count Decreased |
3.8% |
| Pneumonia |
3.8% |
| Renal Failure |
3.8% |
| Respiratory Failure |
3.8% |
| Septic Shock |
3.8% |
| Urine Output Decreased |
3.8% |
| Vomiting |
3.8% |
|
